[1] CHAO Y,WU C,WANG J P,et al. A randomized controlled trial of gemcitabine plus cisplatin versus gemcitabine alone in the treatment of metastatic pancreatic cancer[J]. Cancer Chemoth Pharm,2013,72(3):637-642.
[2] LI H B,ZHOU J,ZHAO F Q. A prognostic nomogram for disease-specific survival in patients with pancreatic ductal denocarcinoma of the head of the pancreas following pancreaticoduodenectomy[J]. Med Sci Monit,2018,24:6313-6321.
[3] BANG U C,BENFIELD T,HYLDSTRUP L,et al. Mortality,cancer,and comorbidities associated with chronic pancreatitis:a Danish nationwide matched-cohort study[J]. Gastroenterology,2014,146(4):989-994.
[4] AROLDI F,BERTOCCHI P,SAVELLI G,et al. Pancreatic cancer:new hopes after first line treatment[J]. World J Gastrointest Oncol,2016,8(9):682-687.
[5] WANG Y,HU G,ZHANG Q,et al. Efficacy and safety of gemcitabine plus erlotinib for locally advanced or metastatic pancreatic cancer:a systematic review and meta-analysis[J]. Drug Des Devel Ther,2016,13(10):1961-1972.
[6] 陈果,熊俊杰,杜玲,等.dCK基因 A9846G 单核苷酸多态性与胰腺癌吉西他滨化疗预后的相关性[J]. 武警后勤学院学报(医学版),2018,27(6):472-476.
[7] PFEIFER G P. Defining driver DNA methylation changes in human cancer[J]. Int J Mol Sci,2018,19(4):1166.
[8] ISOHOOKANA J,HAAPASAARI K M,SOINI Y,et al. Proteins of the retinoblastoma pathway,FEN1 and MGMT are novel potential prognostic biomarkers in pancreatic adenocarcinoma[J]. Pathol Res Pract,2018,214(6):840-847.
[9] GOGGINS M,OVERBEEK K A,BRAND R,et al. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium[J]. Gut,2020,69(1):7-17.
[10] 王灵芝,唐松云,涂剑,等. 吉西他滨联合替吡法尼治疗胰腺癌的有效性和安全性的Meta分析[J]. 上海医药,2020,41(5):34-39.
[11] NEVALA-PLAGEMANN C,HIDALGO M,GARRIDO LAGUNA I. From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer[J]. Nat Rev Clin Oncol,2020,17(2):108-123.
[12] MOTOI F,UNNO M. Adjuvant and neoadjuvant treatment for pancreatic adenocarcinoma[J]. Jpn J Clin Oncol,2020,50(5):483-489.
[13] HU H,GU Y,QIAN Y,et al. DNA-PKcs is important for Akt activation and gemcitabine resistance in PANC-1 pancreatic cancer cells[J]. Biochem Biophys Res Commun,2014,452(1):106-111.
[14] JIN S F,FAN Z K,PAN L,et al. Gemcitabine-based combination therapy compared with gemcitabine alone for advanced pancreatic cancer:a meta-analysis of nine randomized controlled trials[J]. Hepatobiliary Pancreat Dis Int,2017,16(3):236-244.
[15] 钟云华,李燕. 改良多重实时荧光定量PCR 法测定抑癌基因MGMT、p16、CDH13和RASSF1A甲基化在肺癌早期诊断中的作用[J]. 东南大学学报(医学版),2019,38(1):33-38.
[16] CHEN L,WANG Y,LIU F,et al. A systematic review and meta-analysis:association between MGMT hypermethylation and the clinicopathological characteristics of non-small-cell lung carcinoma[J]. Sci Rep,2018,8(1):1439.
[17] QI F,YIN Z,WANG G,et al. Clinical and prognostic significance of O6-Methylguanine-DNA methyltransferase promoter methylation in patients with melanoma:a systematic meta-analysis[J]. Ann Dermatol,2018,30(2):129-135.
[18] ZHANG Y,TONG T. Clinical significance of O-6-methylguanine-DNA-methyltransferase promoter methylation in patients with esophageal carcinoma:a systematic meta-analysis[J]. Dig Dis,2018,36(2):89-97.
[19] 祁志荣,李远良,王超,等. MGMT不同表达水平与替莫唑胺对胃肠胰神经内分泌肿瘤疗效的相关性[J]. 现代肿瘤医学,2021,29(11):1919-1923. |
